Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

Caboxen is identified as a cabozantinib product presented in 20 mg and 80 mg strengths. Cabozantinib is a targeted anticancer medicine belonging to the tyrosine kinase inhibitor class.

The manufacturer plays an important role in pharmaceutical product development, manufacturing quality, packaging, product documentation, and distribution.

This page explains the importance of manufacturer information and the details that should be verified when evaluating Caboxen.

1. About the Caboxen Manufacturer

Manufacturer information is an essential part of pharmaceutical product identification.

At present, the manufacturer of Caboxen has not been independently confirmed through reliable product-specific documentation. Therefore, a manufacturer name, company history, manufacturing location, or certification should not be assumed.

The manufacturer’s identity should be established using the original product packaging and official documentation.

2. Why Manufacturer Information Matters

Knowing the manufacturer of a prescription medicine helps patients, pharmacists, and healthcare professionals identify the product and assess its documentation.

Manufacturer information helps with:

  • Product identification.
  • Manufacturing traceability.
  • Quality documentation.
  • Batch identification.
  • Product safety information.
  • Regulatory verification.
  • Pharmaceutical distribution.
  • Reporting product-quality concerns.

Patients should check the manufacturer’s details before using Caboxen.

3. Caboxen Product Information

The following information describes the product as currently identified on this website.

Product detailInformation
Brand nameCaboxen
Active ingredientCabozantinib
Strengths presented20 mg and 80 mg
Therapeutic categoryAnticancer medicine
Pharmacological classTyrosine kinase inhibitor
Administration routeOral, as identified for cabozantinib products
Dosage formRequires confirmation
ManufacturerNot independently confirmed
Manufacturing countryNot independently confirmed
Regulatory authorizationRequires verification

4. Manufacturing Quality and Pharmaceutical Standards

Prescription anticancer medicines must meet applicable pharmaceutical manufacturing and quality requirements.

Manufacturing quality systems are intended to ensure that medicines are consistently produced and controlled according to appropriate standards.

Important quality considerations include:

Raw Material Quality

Pharmaceutical manufacturing requires appropriate controls over the materials used to produce the medicine.

Manufacturing Processes

Manufacturing operations should follow documented procedures and suitable quality-control requirements.

Product Testing

Finished medicines should undergo appropriate quality testing to assess whether they meet their established specifications.

Packaging and Labeling

Packaging should provide accurate product identification, strength, batch information, expiry details, and relevant handling instructions.

Batch Traceability

Batch identification supports the investigation of product-quality concerns and the traceability of manufactured medicines.

These are general pharmaceutical quality principles and should not be interpreted as confirmation of specific certifications or manufacturing standards for Caboxen.

5. Good Manufacturing Practice (GMP)

Good Manufacturing Practice (GMP) refers to standards and procedures designed to support consistent pharmaceutical product quality.

GMP principles generally cover:

  • Manufacturing facilities.
  • Equipment maintenance.
  • Personnel training.
  • Raw material controls.
  • Production procedures.
  • Quality testing.
  • Packaging operations.
  • Documentation.
  • Storage and distribution.

The actual GMP status of a particular Caboxen manufacturing facility should be verified through appropriate regulatory documentation.

6. Manufacturer Responsibilities

A pharmaceutical manufacturer is generally responsible for ensuring that its products are manufactured and controlled according to applicable regulatory requirements.

Depending on the applicable authorization and manufacturing arrangements, responsibilities may include:

  • Maintaining manufacturing quality systems.
  • Controlling raw materials.
  • Conducting appropriate quality testing.
  • Maintaining batch manufacturing records.
  • Ensuring appropriate packaging and labeling.
  • Providing product information.
  • Investigating quality complaints.
  • Supporting product recalls when required.
  • Complying with applicable regulatory obligations.

These responsibilities help protect patients and maintain pharmaceutical product quality.

7. Importance of Caboxen Product Documentation

Product documentation is necessary to establish the identity and characteristics of Caboxen.

The following documents should be reviewed when available:

  1. Official product information.
  2. Manufacturer identification.
  3. Manufacturing authorization.
  4. Product registration documentation.
  5. Quality-control documentation.
  6. Batch identification records.
  7. Product packaging information.
  8. Storage and handling instructions.
  9. Applicable prescribing information.

The availability and authenticity of these documents should be assessed before the product is prescribed or supplied.

8. Manufacturer and Regulatory Verification

The manufacturer and regulatory status of Caboxen should be confirmed independently.

Verification may involve checking the relevant national medicines regulatory authority and reviewing the manufacturer’s official product documentation.

Important details include:

  • Legal manufacturer name.
  • Manufacturing facility address.
  • Country of manufacture.
  • Product registration number.
  • Marketing authorization holder, where applicable.
  • Approved dosage form.
  • Approved strengths.
  • Product-specific prescribing information.

Registration of another cabozantinib brand does not establish authorization for Caboxen.

9. Understanding the Cabozantinib Product

Cabozantinib is a multi-targeted tyrosine kinase inhibitor.

It acts on several molecular targets, including MET, VEGFR1–3, AXL, RET, and KIT.

These proteins participate in biological processes associated with tumor growth, cellular survival, movement, and blood-vessel formation.

Cabozantinib has established uses in selected cancer-treatment settings, depending on its formulation and applicable regulatory approval.

The approved indications and administration instructions of reference cabozantinib products should not automatically be attributed to Caboxen.

10. Product Strengths and Formulation

Caboxen is presented in two strengths:

  • Caboxen 20 mg.
  • Caboxen 80 mg.

The exact dosage form associated with these strengths must be confirmed from the original packaging.

This distinction is particularly important because established cabozantinib tablets and capsules have different pharmaceutical characteristics and administration instructions.

They are not bioequivalent and should not be substituted for one another.

11. Patient Safety and Manufacturer Verification

Before using Caboxen, patients and healthcare professionals should confirm:

  • The product name.
  • The stated active ingredient.
  • The prescribed strength.
  • The exact dosage form.
  • The manufacturer.
  • The batch number.
  • The expiry date.
  • The integrity of the packaging.
  • Applicable regulatory authorization.
  • Official product instructions.

Patients should avoid using products with missing, inconsistent, or suspicious identification details until they have been professionally assessed.

12. Frequently Asked Questions About the Manufacturer

1. Who manufactures Caboxen?

The manufacturer has not been independently confirmed. The original packaging and official product documentation should be reviewed to establish the manufacturer’s identity.

2. What is the active ingredient in Caboxen?

The stated active ingredient is cabozantinib, a targeted anticancer medicine.

3. What strengths of Caboxen are presented?

Caboxen is presented in 20 mg and 80 mg strengths.

4. Where is Caboxen manufactured?

The manufacturing country has not been independently confirmed.

5. Is Caboxen manufactured according to GMP standards?

Its specific manufacturing facility and GMP certification have not been independently verified. Appropriate regulatory documentation should be obtained.

6. Why is the manufacturer’s identity important?

Manufacturer information supports product identification, manufacturing traceability, quality assessment, and regulatory verification.

7. Does Caboxen have regulatory approval?

Its product-specific regulatory authorization has not been independently confirmed. This should be checked with the relevant national regulatory authority.

8. Are Caboxen and other cabozantinib products identical?

Not necessarily. Products may differ in dosage form, pharmaceutical characteristics, manufacturing arrangements, and regulatory authorization.

9. Can I verify Caboxen using its batch number?

A batch number supports product traceability, but it does not independently establish authenticity. Verification should involve appropriate manufacturer or regulatory documentation.

10. What should I do if manufacturer information is missing?

Consult a qualified pharmacist or the relevant medicines regulatory authority before using the product.

Manufacturer Information Disclaimer

The manufacturer of Caboxen, its manufacturing location, specific quality certifications, and regulatory authorization have not been independently established in the information available for this website.

No company identity, manufacturing history, certification, or quality claim should be published as fact without supporting documentation.